Wilken, O’Shea Talk Acquisition of HS Pharmaceuticals and What It Means for The Future Of XCRT

CEO Mike O’Shea of Xcelerate, Inc., a development stage startup focused on the development of cutting-edge medtech applications, met with SmallCapVoice.com to discuss the recent appointment of a new board member and the acquisition of a rather sizeable patent portfolio

Please leave this field empty

Oh hi there
It’s nice to meet you.

Sign up to receive Company announcements, press releases, and progress reports directly.

We don’t spam! Read our privacy policy for more info.

Check your inbox or spam folder to confirm your subscription.